tbuckley/cabot-search huggingface dataset:
Emergence et dissémination de Staphylococcus aureus USA300 résistant à la méthicilline au Danemark (2000-2005)
Authors: A R Larsen, M Stegger, R V Goering, M Sørum, R Skov
Journal: Eurosurveillance (2007)

Le probleme cause par les Staphylococcus aureus resistants a la methicilline (SARM) ne cesse de croitre dans le monde. La dissemination des SARM dans la population represente un veritable defi en termes de controle des infections d’autant qu’elle n’est plus limitee au milieu hospitalier mais touche egalement les foyers, les lieux de travail et les creches [1]. Par ailleurs, les SARM d’origine communautaire (co-SARM) peuvent entraver le controle des infections au niveau des hopitaux, les tests etant rarement effectues lors de leur admission. Aux Etats-Unis, la souche predominante de CO-SARM est definie par le Center for Disease Control (CDC) comme la souche USA300 (ST8). Cette souche provoque principalement des infections de la peau et des tissus mous (IPTM) essentiellement dans la communaute [2], mais les infections nosocomiales avec cette souche sont en augmentation aux Etats-Unis [3,4]. La comparaison des donnees relatives aux SARM recueillies de 1997 a 2005 au Danemark, avec la souche de reference USA300, a montre que cette derniere a ete introduite au Danemark a plusieurs reprises. Entre 2000 et 2005, 44 isolats ont ete identifies, partageant le meme profil electrophoretique (PFGE) que USA300, ainsi que des caracteristiques moleculaires : spa type t008 ou variants etroitement lies, positifs a la leucocidine de Panton-Valentine (PVL) et possedant la cassette chromosomique mec du staphylocoque (SCCmec) de type IVa. Les isolats causaient des IPTM mais certains cas d’infections invasives ont egalement ete rapportes. 
Entre 2003 et 2005, le nombre de souches USA300 a beaucoup augmente (respectivement 2, 11 et 28 nouveaux cas). Si l’on se refere a la situation aux Etats-Unis, il y a lieu de s’inquieter, d’autant que le Danemark a, de longue date, fait ses preuves pour le controle des SARM.
EXTH-49. IN VIVO ANALYSES OF LONG-TERM STABILITY AND DISTRIBUTION PATTERNS OF L-MYC IMMORTALIZED HUMAN NEURAL STEM CELLS
Authors: Russell Rockne, Vikram Adhikarla, Meher Masihi, Lusine Tsatsuryan, Zhongqi Li, Karen Aboody, Michael Barish, Margarita Gutova
Journal: Neuro-Oncology (2017)

Preclinical studies indicate that neural stem cells (NSCs) can limit or reverse central nervous system (CNS) damage through delivery of therapeutic agents of cell regeneration. Clinical translation of cell-based therapies raises concerns about the long-term stability, absence of tumorigenicity, and manufacturing time required to produce therapeutic cells in quantities sufficient for clinical use. Allogeneic NSC lines are in growing demand due to challenges inherent in employing autologous stem cells, including production costs limiting availability to patients. Here, we demonstrate the long-term stability of L-MYC immortalized human NSCs (LM-NSC008) in vivo, including engraftment, migration, and absence of tumorigenicity of LM-NSC008 cells resident in mouse brains for over nine months. These are all properties favoring potential use of these allogeneic NSCs in clinical settings. We also examined the distributions of engrafted LM-NSC008 cells, and developed computational techniques to analyze NSC migration characteristics in relation to intrinsic brain structure (as assessed by light microscopy). This computational analysis of NSC distributions following implantation provides proof-of-concept for the development of computational models that can be used clinically to predict NSC migration paths in patients. Previously, models of preferential malignant tumor cell migration along white matter tracts have been used to predict their final distributions. We suggest that quantitative measures of tissue orientation and white matter tracts determined from MR images can be used in a diffusion tensor imaging tractography-like approach to describe the most likely migration routes and final distributions of NSCs administered in a clinical setting. Such a model could be very useful in choosing the optimal locations for NSC administration to patients to achieve maximum therapeutic effects.
CSIG-10. MYRISTOYLATED ALANINE-RICH C-KINASE SUBSTRATE PHOSPHORYLATION ENHANCES THE GROWTH AND RADIATION RESISTANCE OF GLIOBLASTOMA
Authors: Nicholas Eustace, Joshua Anderson, Catherine Langford, Patricia Hicks, Anita Hjelmeland, Christopher Willey, John Jarboe
Journal: Neuro-Oncology (2017)
MA 16.01 Characterization of Autoantibody Responses in Thymoma with Myasthenia Gravis by Single-Cell Sequencing of B-cells
Authors: A. Gomez, J. Adamska, S. Padda, J. Preiss, N. Lingampalli, H. Wakelee, W. Robinson
Journal: Journal of Thoracic Oncology (2017)
Evaluation de l’impact sur la mortalité de la vague de chaleur de 2003 en France
Authors: P Pirard, S Vandentorren, M Pascal, K Laaidi, A Le Tertre, S Cassadou, M Ledrans
Journal: Eurosurveillance (2005)

Une periode caniculaire d’une intensite exceptionnelle est survenue en France entre le 2 et le 15 aout 2003. Toutes les regions francaises ont ete touchees par cette vague de chaleur, qui a provoque un exces de 14 800 deces entre le 1er et le 20 aout. La tendance de la courbe de mortalite etait parallele a la courbe des temperatures. La mortalite observee a la derniere decade du mois d’aout et dans les trois mois qui ont suivi est revenue a un niveau habituel. L’impact sanitaire de cette vague de chaleur variait considerablement d’une ville a l’autre. La duree et l’intensite exceptionnelle des temperatures minimales ne suffisent pas a expliquer toute la surmortalite observee. Les femmes âgees de plus de 75 ans ont ete les plus touchees. Les ratios de mortalite les plus importants ont ete observes pour des causes de deces directement attribuables a la chaleur. Devant l’ampleur de l’impact sanitaire de cette vague de chaleur, les autorites sanitaires francaises ont mis en place en 2004 un systeme d’alerte national ainsi qu’un plan d’action preventive dans chaque region.
P2.03-010 Updated Survival Outcomes of NEJ005/TCOG0902, a Randomized PII of Gefitinib and Chemotherapy in EGFR-Mutant NSCLC
Authors: T. Fukuhara, S. Oizumi, S. Sugawara, K. Minato, T. Harada, A. Inoue, Y. Fujita, S. Watanabe, K. Ito, A. Gemma, Y. Demura, M. Harada, H. Isobe, I. Kinoshita, S. Morita, K. Kobayashi, K. Hagiwara, M. Kurihara, T. Nukiwa
Journal: Journal of Thoracic Oncology (2017)
La surveillance de la syphilis et l’évolution de l’épidémie en Allemagne depuis le milieu des années 1990
Authors: U Marcus, V Bremer, O Hamouda
Journal: Eurosurveillance (2004)

Les rapports de surveillance recents d’Europe et des Etats-Unis montrent un accroissement des cas de syphilis. Il est essentiel de disposer de donnees epidemiologiques precises sur la distribution de la syphilis pour cibler les programmes de depistage et d’interventions. Le systeme de notification allemand de la syphilis a ete modifie en 2001, se basant a present sur les declarations des laboratoires, et non plus des medecins. Ce changement se double d’un nouveau systeme sentinelle des infections sexuellement transmissibles (IST). 
Apres avoir atteint le taux de notifications le plus bas dans les annees 1990, les declarations de syphilis ont repris de facon significative depuis 2001, date qui coincide avec l’introduction du nouveau systeme de notification. L’augmentation de l’incidence reflete toutefois une veritable augmentation du nombre de cas et n’est pas due seulement a la sous-notification du systeme precedent. Cette hausse concerne des epidemies de syphilis chez les hommes ayant des relations sexuelles avec d’autres hommes (HSH). La premiere epidemie a eu lieu a Hambourg en 1997. En 2003, l’incidence etait dix fois plus elevee chez les hommes que chez les femmes. On estime que 75% des cas de syphilis diagnostiques actuellement concernent des HSH. Une forte proportion de ces patients (jusqu’a 50% selon les donnees du systeme sentinelle) sont seropositifs pour le VIH. Le nombre continuellement eleve, compare a d’autres pays d’Europe occidentale, de cas de syphilis diagnostiques chez des heterosexuels en Allemagne dans les dernieres annees pourrait etre du aux mouvements de populations plus importants entre l’Allemagne et des regions ayant une incidence elevee de syphilis, a l’est et au sud-est de l’Europe.
SURG-19. THE SURGICAL OUTCOME OF BRAIN TUMORS LOCATED WITHIN OR ADJACENT TO THE MOTOR PATHWAYS OPERATED VIA AWAKE VS. GENERAL ANESTHESIA
Authors: Rachel Grossman, Zvi Ram, Roni Zelitzki
Journal: Neuro-Oncology (2017)

Surgical removal of intra-axial brain tumors aims at maximal tumor resection while preserving function. The potential benefit of awake-craniotomy for motor preservation is yet unknown. This study compares motor outcome of patients undergoing awake surgery for tumors to patients who are operated under general anesthesia using awake vs. anesthetized. Data from 85 patients with full dataset who underwent resections of tumors within or adjacent to motor pathways, in a single institution between 2004-2015 were retrospectively reviewed. with electrophysiological monitoring for motor function was used in both groups. High-grade gliomas was the most common pathology treated. Identification of the motor cortex required significantly higher stimulation threshold in anesthetized patients (6.2 ± 2.7 mA vs. 9.1 ± 4, p=0.0008). Similarly, the distance of the resection cavity from the pyramidal tracts was significantly shorter in the awake patients (9.8 cm ± 8.8 vs. 14.3 cm ± 9.8, p=0.03). However, extent of resection (EOR) was not different between groups. Post-operative motor function at 1 week was worse in the anesthetized patients (p=0.046), but was not different between groups at 3 months. Awake-craniotomy is a safe method that results in a better early post-operative motor outcome compared with patients undergoing surgery under general anesthesia. However, long-term outcome and EOR are not different between the two surgical techniques.
HOUT-17. A PRELIMINARY DATA REPORT ON A PHASE 2 STUDY OF ERC1671 IN RECURRENT GLIOBLASTOMA
Authors: Daniela Bota, Jinah Chung, Jose Carrillo, Xiao-Tang Kong, Beverly Fu, Chrystel Pretto, Ankie Strik, Virgil Schijns, Apostolos Stathopoulos
Journal: Neuro-Oncology (2017)

Standard therapy for recurrent GBM is bevacizumab, a monoclonal VEGF inhibitor that targets tumor vasculature. The response to bevacizumab is transient and short-lived after which patients typically develop progressive physical and mental debilitation culminating in death. ERC1671 is an allogeneic/autologous therapeutic vaccine – composed of whole, inactivated tumor cells mixed with tumor cell lysates. The proposed action of ERC1671 is the stimulation of the patients’ immune system. This ongoing phase 2 study has a goal to determine the safety and effectiveness of ERC1671 in combination with GM-CSF and cyclophosphamide as an add-on treatment to bevacizumab for recurrent GBM. ERC1671/GM-CSF is intradermally administered 2-3 times a week and for five total into maximum 18 days, while cyclophosphamide is orally administered for 4 days at the beginning. GM-CSF dose is 250 µg/m2 and cyclophosphamide dose is 50 mg/day. Bevacizumab is administered as standard of care at 10 mg/kg every 2 weeks. The treatment cycle is 28 days. 9 recurrent bevacizumab-naïve GBM patients, with KPS higher than 70, were treated with ERC1671/GM-CSF/Cyclophosphamide + Bevacizumab v. Placebo + Bevacizumab. Median age was 59 (48-74), with 2 patients being female, and the average KPS 80 (70-100). These patients were unblinded at the time of further progression – 4 received vaccine, 4 received placebo, and 1 was non-evaluable due to discontinuation prior to completion of 1 cycle. Overall survival of patients treated with ERC1671 + Bevacizumab was more than 513 days, compared to patients treated with Placebo + Bevacizumab was 213 days (p=0.048). First clinical results for toxicity show an equal distribution of AEs between the Vaccine and Placebo groups, with no Gr4/Gr5 AEs. The addition of ERC1671/GM-CSF/Cyclophosphamide to bevacizumab for recurrent glioblastoma resulted in a clinically meaningful survival benefit with minimal additional toxicity. The phase 2 randomized, double-blinded study is ongoing with anticipated 2 subsites.
DDIS-08. THE SMALL MOLECULE IMIPRIDONE ONC201 IS ACTIVE IN GLIOBLASTOMA WITH DRD2 PATHWAY DYSREGULATION
Authors: Varun Vijay Prabhu, Neel Madhukar, C Leah B Kline, Rohinton S Tarapore, Wafik El-Deiry, Olivier Elemento, Joseph Rucker, Benjamin Doranz, Faye Doherty, Alexander VanEngelenburg, Jessica Durrant, Cyril Benes, Isabel Arrillaga-Romany, Wolfgang Oster, Joshua E Allen
Journal: Neuro-Oncology (2017)

ONC201, an imipridone that is a selective antagonist of the G protein-coupled receptors dopamine receptor D2 (DRD2) and D3 (DRD3), has exhibited tumor shrinkage and an exceptional safety profile in a phase II recurrent glioblastoma clinical trial (Arrillaga et al, 2017). In vitro and in vivo studies have previously demonstrated single agent ONC201 efficacy in glioblastoma models (Allen et al 2013). In vitro efficacy profiling of ONC201 in the Genomic of Drug Sensitivity in Cancer (GDSC) collection of cell lines confirmed broad anti-cancer efficacy with high sensitivity in human brain cancer cell lines. DRD2 is overexpressed in glioblastoma and DRD2 antagonism induces tumor cell apoptosis via the same signaling pathways that respond to ONC201. Investigation of The Cancer Genome Atlas (TCGA) revealed that DRD2 is highly expressed in glioblastoma relative to other dopamine receptor family members and that genetic aberrations were rare. High expression of DRD2 occurred in primary, rather than secondary, glioblastoma and was associated with a poor prognosis. Immunohistochemistry analyses of tissue microarrays revealed DRD2 overexpression in glioblastoma relative to normal brain. A linear correlation between DRD2 mRNA and ONC201 GI50 was observed among glioblastoma cell lines in the NCI60 panel. A significant induction of serum prolactin, a surrogate biomarker of target engagement, was detected in ONC201-treated glioblastoma patients. Interestingly, expression of DRD5, a D1-like dopamine receptor that counteracts DRD2 signaling, was significantly inversely correlated with ONC201 potency in the NCI60 and GDSC datasets (P <.05). Furthermore, a missense DRD5 mutation was identified in cancer cells with acquired resistance to ONC201. Resistance could be recapitulated with overexpression of the mutant DRD5 gene or, to a lesser extent, with the wild-type gene. In conclusion, the DRD2 pathway is a therapeutic target that is dysregulated in glioblastoma and contains biomarkers of tumor sensitivity to ONC201 that are under clinical evaluation.
MA 03.01 Nab-Paclitaxel ± CC-486 as Second-Line Treatment of Advanced NSCLC: Results from the ABOUND.2L+ Study
Authors: D. Morgensztern, M. Cobo Dols, S. Ponce Aix, P.E. Postmus, J. Bennouna, J. Fischer, O. Vidal, D. Stewart, G. Fasola, J. Weaver, M. Wolfsteiner, T.J. Ong, R. Govindan
Journal: Journal of Thoracic Oncology (2017)
Mejorar un sistema nacional de vigilancia de salud pública mediante un “círculo de calidad”
Authors: G Krause, J Benzler, G Reiprich, R Görgen
Journal: Eurosurveillance (2006)

Los sistemas de vigilancia de las enfermedades infecciosas son la base para llevar a cabo medidas eficaces de salud publica en terminos de prevencion y control de dichas enfermedades. La evaluacion y la mejora de la calidad de los sistemas de vigilancia nacionales son un desafio, teniendo en cuenta el numero de administraciones y profesiones que contribuyen a un sistema complejo en lo cual se deben intercambiar informaciones sensibles, de manera fiable y rapida. Se organizo una evaluacion pluridisciplinaria, (llamada circulo de calidad) del sistema nacional aleman de salud publica, incluyendo medicos clinicos, de laboratorio y personal de servicios sanitarios locales y nacionales, asi como del Instituto Robert-Koch. Las recomendaciones que se hicieron al final de esta evaluacion incluyeron modificaciones de la Ley Federal de control de las enfermedades infecciosas, asi como cambios en aspectos practicos como el cambiar los formularios de notificacion y enviar cartas de informacion por fax a los medicos clinicos. Desde entonces se implementaron algunas recomendaciones, produciendose notables mejoras. Esta experiencia muestra que la aplicacion del metodo del circulo de calidad es una herramienta util para mejorar la calidad de los sistemas nacionales de vigilancia de la salud publica.
A vigilância das infecções invasivas meningocócicas na República Checa
Authors: P Kriz
Journal: Eurosurveillance (2004)

A notificacao de rotina das infeccoes meningococicas invasivas tem uma grande tradicao na Republica Checa, estando disponiveis dados de mortalidade desde 1921 e de morbidade desde 1943. No laboratorio nacional de referencia das infeccoes meningococicas de Praga, ficam conservadas desde 1970 mais de 3 500 estirpes de Neisseria meningitidis originarias de casos de infeccoes invasivas e de seus contactos, de portadores sâos e de casos de infeccoes respiratorias. A analise dessas estirpes mostra que a populacao afectada por esta doenca na Republica Checa e diferente daquela observada na Europa occidental. Em 1993, a incidencia das infeccoes meningococicas de serogrupo C aumentou. Este aumento esta associado a emergencia do complexo Neisseria meningitidis C, ST-11, ET- 15/37, extremamente virulento. Este complexo foi responsavel do aumento da incidencia da infeccao meningococica, que atingiu o seu valor maximo em 1995 (2,2/100.000). Em consequencia, estabeleceu-se no pais uma strategia vacinal dirigida a populacao com o maior risco para estas infeccoes meningococicas invasivas.
ACTR-37. PREDICTIVE SIGNIFICANCE OF IDH1/2 MUTATION AND 1p/19q CO-DELETION STATUS IN A POST-HOC ANALYSIS OF NRG ONCOLOGY/RTOG 9802: A PHASE III TRIAL OF RT VS RT + PCV IN HIGH RISK LOW-GRADE GLIOMAS
Authors: Erica H Bell, Peixin Zhang, Edward G Shaw, Jan C Buckner, Geoffrey R Barger, Stephen W Coons, Dennis E Bullard, Minesh P Mehta, Mark R Gilbert, Paul D Brown, Keith J Stelzer, Jessica Fleming, Joseph P McElroy, Cynthia D Timmers, Aline Paixao Becker, Andrea L Salavaggione, Ziyan Liu, Ken Aldape, David G Brachman, Stanley Z Gertler, Albert D Murtha, Christopher J Schultz, David Johnson, Hui-Kuo Shu, Arnab Chakravarti
Journal: Neuro-Oncology (2017)

This study investigated the predictive significance of IDH1/2 mutations and 1p/19q co-deletion in patients with high risk (age≥40 or subtotal resection/biopsy) low-grade gliomas (LGGs), randomized to receive RT with or without PCV after biopsy/surgical resection in NRG Oncology/RTOG 9802. Importantly, this is the very first phase III study to analyze the predictive value of these sub-groups in LGGs using prospectively-collected, well-annotated clinical data. Immunohistochemistry and/or IonTorrent sequencing were used to determine IDH1/2 status. Oncoscan and/or 450K methylation data were used to determine 1p/19q status. To estimate by marker status the treatment effect on overall survival (OS) and progression-free survival (PFS), hazard ratios (HRs) were calculated using the Cox proportional hazard model and tested using the log-rank test in a post-hoc and exploratory analysis. Interaction effects between marker status and treatment were tested. Of all the randomized eligible patients in NRG Oncology/RTOG 9802, 97(39%) had sufficient DNA for profiling. Of these, 36(37%) were IDHmut/non-co-deleted, 33(34%) were IDHmut/co-deleted, and 28(29%) were IDHnon-mut. Upon univariate analyses, the IDHmut/non-co-deleted sub-group was significantly correlated with better PFS with the addition of PCV (HR=0.31; p=0.005) and OS (HR=0.36; p=0.02). The IDHmut/co-deleted sub-group was significantly correlated with better PFS with the addition of PCV (HR=0.16; p=0.002), but not OS (HR=0.31; p=0.13). There was no significant difference observed with the addition of PCV in the IDHnon-mut sub-group for either OS or PFS. Tests on interaction effects revealed no statistical significance. Our analyses suggest a putative predictive value of 1p/19q co-deletion and IDH1/2 mutations for high-risk LGGs, based on the observed differences in the treatment effect by marker status. Our results also support the hypothesis that IDHnon-mut high-risk LGG patients do not benefit from the addition of PCV to RT. FUNDING: U10CA21661, U10CA180868, U10CA180822, and U10CA37422. Also, R01CA108633, R01CA169368, RC2CA148190, U10CA180850-01, BTFC, OSU-CCC (all to AC).
OA 17.06 Updated Analysis of KEYNOTE-024: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced NSCLC With PD-L1 TPS ≥50%
Authors: J. Brahmer, D. Rodríguez-Abreu, A. Robinson, R. Hui, T. Csőszi, A. Fülöp, M. Gottfried, N. Peled, A. Tafreshi, S. Cuffe, M. O'Brien, S. Rao, K. Hotta, A. Riccio, J. Yang, M.C. Pietanza, M. Reck
Journal: Journal of Thoracic Oncology (2017)
P3.01-049 T790M Mutation Detection, Clinical Characteristics and Impact in NSCLC Patients Treated with EGFR Tyrosine Kinase Inhibitors
Authors: L. Bei, J. Oliveira, M. Pinheiro, I. Veiga, A. Peixoto, P. Rocha, C. Oliveira, A. Rodrigues, I. Pousa, I. Azevedo, R. Henrique, M. Teixeira, M. Soares
Journal: Journal of Thoracic Oncology (2017)
Epidémie de fièvre Q à Lohra-Rollshausen, Allemagne, printemps 1996
Authors: O Lyytikaïnen, T Ziese, B Schwartländer, P Matzdorff, C Kuhnhen, C Burger, W Krug, L R Petersen
Journal: Eurosurveillance (1997)

La fievre Q est une maladie febrile aigue, parfois chronique, due a une rickettsie, Coxiella burnetii. Les reservoirs animaux les plus courants de C. burnetii sont les bovins, les moutons et les chevres. L'organisme est diffuse particulierement dans les produits de parturition des animaux infectes. C. burnetii resiste a la dessiccation. Les humains sont infectes principalement par l'inhalation de poussieres et d'aerosols contamines (1). En mai 1996, le service de sante de Marburg-Biedenkopf dans l'etat de Hessen a ete informe d'un foyer de patients presentant une fievre elevee et persistante survenu a Rollshausen et dans les villes environnantes. Les analyses serologiques de certains patients, effectuees par les autorites sanitaires locales, suggeraient des cas de fievre Q. En juillet 1996, l'Institut Robert Koch a ete sollicite pour participer a l'investigation de ce foyer afin de verifier qu'une epidemie de fievre Q avait reellement eu lieu a Rollshausen et d'evaluer les facteurs de risques potentiellement associes.